title: Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle.
abstract: Several compounds have been identified that inhibit an early stage in the replicative cycle of the human immunodeficiency virus (HIV): i) virus adsorption: polysulfates, polysulfonates, polycarboxylates, polyphosphates, and polyoxometalates; or ii) virus-cell fusion: plant lectins, negatively charged albumins and betulinic acid derivatives; iii) virus fusion/uncoating: bicyclam derivatives; iv) reverse transcription: dideoxynucleoside analogues, acyclic nucleoside phosphonates and non-nucleoside reverse transcriptase inhibitors. In principle, HIV may develop resistance to any of these specific anti-HIV agents. However, virus breakthrough can be completely prevented if these agents, alone or in combination, are added to the HIV-infected cells from the beginning at sufficiently high ('knock-out') concentrations.
authors.affiliation: Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: De Clercq
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006678:HIV / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D014158:Transcription, Genetic / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents